NCT05241067View on ClinicalTrials.gov

Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDS

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
DRUG

Normal Saline

Placebo (Dose: equal volume saline) + Standard of care

DRUG

Centhaquine

Centhaquine (Dose: 0.01 mg/kg) + Standard of care

Sponsors

Lead Sponsor

Pharmazz, Inc.
All Listed Sponsors
lead

Pharmazz, Inc.

INDUSTRY